Citalopram Teva (Escitalopram) is applied in clinical settings that involve acute or unstable symptom patterns of emotional distress and functional impairment. It offers symptomatic support across several key mental health domains. It provides supportive relief when symptoms interfere with routine activities and supports general well-being during symptomatic phases.

The medication is utilized in the management of Major Depressive Disorder and Generalized Anxiety Disorder. It is also relevant in managing symptoms associated with recurrent or episodic manifestations of fear, particularly Panic Disorder, Social Anxiety Disorder (SAD), and Obsessive-Compulsive Disorder (OCD). It is applied in contexts where additional symptomatic support is needed for symptom management.

“The therapy is relevant when supportive symptom management is appropriate, as it may assist with maintaining functional stability during difficult episodes.”

---

Key Therapeutic Domains

The medication is commonly used across conditions characterized by periods of heightened symptoms of major depressive illness, where it may assist with managing symptoms that create noticeable functional strain, and contributes to easing the overall symptom load of persistent low mood. It is also relevant for increased discomfort or tension due to Generalized Anxiety Disorder, where it provides support that may help ease distress.

Symptom Support: Managing Chronic Worry

The drug is relevant in settings where excessive, pervasive worry and chronic mental tension become difficult to tolerate, and may assist with maintaining functional stability.

Eligibility and Contraindications

The eligibility to use Citalopram Teva (Escitalopram) is strictly defined by regulatory authorities based on population age, concurrent medications, and pre-existing health conditions.

Classification	Official Status
Approved Adult Use	Established for adults (18+ years) [Source 1.3].
Pediatric Use	Established for adolescents (12–17 years) for MDD and children (7+ years) for GAD. Safety is not established for younger children [Source 2.2].
Older Adults (65+)	Use requires caution and a lower maximum recommended dose [Source 1.2, 2.3].
Hepatic Impairment	Use requires caution; a lower maximum recommended dose is specified [Source 1.3].
Severe Renal Impairment	Use with caution due to limited data [Source 1.3].

Absolute Prohibitions (Contraindications)

Citalopram Teva must not be used by certain populations, primarily due to high risk of severe reactions:

• Hypersensitivity: Patients with a known allergy to escitalopram, citalopram, or any component of the formulation [Source 1.3, 2.6].
• MAOIs and Pimozide: Patients currently taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, or the medicine pimozide [Source 1.3, 2.6].
• QT Prolongation Risk: Individuals with congenital long QT syndrome or known acquired QT interval prolongation, or those taking other QT-prolonging medicines [Source 2.3, 2.6].

Pregnancy and Lactation Status

Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus [Source 1.3]. Caution should be exercised when the medicine is administered to a nursing woman [Source 1.3].

Citalopram should not be used in combination with several classes of medications due to the risk of serious adverse events. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic Linezolid and intravenous Methylene Blue, is strictly contraindicated due to the potential for a life-threatening reaction known as Serotonin Syndrome. A washout period of at least 14 days is required when switching between Citalopram and an MAOI.

Citalopram is also contraindicated with certain drugs, such as Pimozide, and other agents known to prolong the QTc interval (a measure of heart rhythm), as Citalopram itself causes dose-dependent QTc prolongation, which increases the risk of serious heart arrhythmias like Torsade de Pointes. The maximum recommended daily dose is restricted to 20 mg for patients over 60 years old, those with hepatic impairment, or individuals taking CYP2C19 inhibitors like Cimetidine, as these factors can increase Citalopram exposure.

Caution is advised with other medications that increase serotonin activity, such as Triptans or other antidepressants, as well as the herbal supplement St. John’s wort, all of which can increase the risk of Serotonin Syndrome. Concomitant use with anticoagulants (e.g., Warfarin) and other drugs that affect blood clotting, such as NSAIDs or Aspirin, may increase the risk of bleeding events.

The mechanism of Citalopram Teva initiates by modulating serotonergic signaling within the central nervous system (CNS). The action is characterized by an initial molecular blockade followed by a slower, adaptive restructuring of nerve cell communication.

---

Selective Serotonin Transporter Inhibition

Citalopram Teva operates as a selective inhibitor by binding to the serotonin transporter (SERT) protein on the surface of presynaptic nerve cells. This action blocks the reabsorption (reuptake) of the neurotransmitter serotonin (5-HT) from the synaptic gap. The blockade results in an increased concentration and duration of serotonin available for transmission across the synapse.

---

Neuroplasticity and Functional Adaptation

This increased concentration of serotonin drives a subsequent, slower adaptive change in the brain. The continuous signaling prompts the desensitization of certain serotonin receptors (autoreceptors) and promotes neuroplasticity within key pathways over time. These complex structural and functional adjustments modify the regulation of signaling dynamics within the affected neural circuits, achieving a sustained shift in monoamine homeostasis.

Citalopram Teva is administered orally and should be taken as a single dose once daily, either in the morning or evening. The medication may be taken with or without food, as its absorption is not affected by meals. For consistency, it is recommended to take the dose at approximately the same time each day.

Official Dosing and Administration

Patient Population	Initial Daily Dose	Maximum Daily Dose
General Adults	20 mg	40 mg
Elderly Patients (Age > 60)	10 mg to 20 mg	20 mg
Hepatic Impairment	10 mg (for first two weeks)	20 mg

The standard adult treatment initiates at 20 mg once daily. The dose may be increased to a maximum of 40 mg once daily after a minimum interval of one week, following established protocols. The maximum daily dose of 40 mg should not be exceeded in the general population, and a lower maximum dose of 20 mg is mandated for patients over 60 years of age, those with hepatic impairment, or individuals taking concomitant CYP2C19 inhibitors.

If the tablet formulation is used, it should be swallowed whole. If the oral solution is prescribed, the bottle should be shaken well before measurement, and an accurate, marked measuring device must be used to ensure the correct dose is administered. If a dose is missed, the standard procedure is to skip the missed dose and continue with the regular schedule if it is almost time for the next dose; do not take two doses to make up for the forgotten one.

Research Evidence / Overview of Studies

---

Research and Mechanism of Action

Research suggests Citalopram may influence neurotransmission by acting as a Selective Serotonin Reuptake Inhibitor (SSRI). Studies explored the compound's pharmacodynamics, focusing on its interaction with serotonin pathways associated with mood regulation and anxiety.

---

Clinical Efficacy and Outcomes

Studies have evaluated the compound for tolerability and potential impact across various mood and anxiety disorders.

Major Depressive Disorder (MDD) Data

• Primary Endpoint: Change in symptom severity, typically measured by the Hamilton Rating Scale for Depression (HAM-D).
  • Primary clinical trials reported that participants experienced a change in HAM-D scores over 6 to 8 weeks of treatment.
  • The magnitude of this change was compared to placebo groups in controlled studies.
• Secondary Endpoint: Global improvement in clinical status.
  • In study participants, results from measures like the Clinical Global Impression (CGI) tool were analyzed and reported compared to baseline measurements.

Extended Use Evaluation

Long-term studies have explored the compound's use in maintenance protocols following acute response. The primary goal of these evaluations was to monitor long-term tolerability and observe changes in participant symptoms over periods exceeding six months.

---

Safety and Tolerability Profile

Research indicates the compound was evaluated for use in adult populations. Research monitored specific adverse events. The events reported most frequently included nausea, dry mouth, and insomnia. Most reported events were classified as mild to moderate in severity, and their frequency was observed to decrease over time with continued use.

Common questions about Citalopram Teva (FAQ)

Q: What are the common side effects of this medication?

According to the official product information, the most commonly reported side effects observed during clinical studies were [specific side effect 1], [specific side effect 2], and [specific side effect 3]. It is important to remember that side effects can vary greatly between individuals, and not everyone will experience them. A complete list of observed effects is provided in the 'Possible side effects and safety information' section of the official product label.

Q: Can I take this drug if I am also taking drug 'Y'?

Regulatory documents indicate that this medication is known to have a potential interaction with drug 'Y'. Using them together may lead to [specific clinical consequence, e.g., increased risk of bleeding] and therefore should be approached with caution. Healthcare professionals are best positioned to review all medicines an individual is currently taking.

Q: Does taking this drug with food affect how it works?

Studies and official information indicate that this medicine can be taken with or without food. Taking it alongside a meal or on an empty stomach does not significantly change how the medicine is absorbed by the body. Individuals should follow the instructions provided by a healthcare provider regarding administration.

Q: What should I do if I miss a dose?

The official product monograph states that a missed dose may be taken as soon as it is remembered. However, if the next scheduled dose is approaching, the missed dose should typically be skipped. Taking two doses at the same time to compensate for a missed dose is not recommended in the product label.

How to Store and Dispose of Citalopram Teva?

Citalopram Teva tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It is required to keep the medicine in its container, which must be closed tightly, and protected from excess heat, moisture, and direct light. The product must be stored in a secure location, out of the sight and reach of children and pets, and must not be allowed to freeze.

For disposal of unused or expired tablets, the preferred method is to use a formal drug take-back program or mail-back service. Citalopram is not included on the official FDA flush list. If household disposal is necessary, the medicine must first be mixed with an undesirable substance, placed in a sealable bag or container, and then thrown in the trash. Personal information must be removed from the original packaging.